logo Hematology/Oncology Research Studies: Open for Enrollment Date: 09/19/19


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice): Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations

NCT#/Phase: NCT03213691
Phase 2
IRB#: 2017-095e
Description: This is a subprotocol of the MATCH trial APEC1621 and is a phase 2 trial of selumetinib (AZD6244 hydrogen sulfate) in children with recurrent or refractory solid tumors (including non-Hodgkin lymphomas,histiocytoses and CNS tumors) harboring specified activating genetic alterations of the MAPK signaling pathway. The study aims to determine the objective response rate of Selumetinib (AZD6244 hydrogen sulfate), a potent orally bioavailable small molecule inhibitor against ERK activation by activated MEK proteins.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621E.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group
Principal Investigator(s): Carla Golden, MD
Contact(s): Christine Ho (510-428-3885 x 2609)
Diane Olzewski (510-428-3885 x 3246)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03213691#

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000